Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Chunghwa Chemical Synthesis & Biotech Co 5-Year Yield-on-Cost % Related Terms
TPE:1762 vs VRTX, REGN, RVMD: 5-Year Yield-on-Cost % Comparison
For the Biotechnology subindustry, Chunghwa Chemical Synthesis & Biotech Co's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chunghwa Chemical Synthesis & Biotech Co 5-Year Yield-on-Cost % vs Biotechnology Industry
Chunghwa Chemical Synthesis & Biotech Co 5-Year Yield-on-Cost % Calculation
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) has a 5-Year Yield-on-Cost % of 0.14 as of Aug. 12, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. This is 77% below median its historical median of 0.60. Over the past decade, Chunghwa Chemical Synthesis & Biotech Co's 5-Year Yield-on-Cost % has ranged from 0.12 to 1.90. According to the industry distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #140 out of 150 companies in the Biotechnology industry, placing it in the top 93.3%.
Is Chunghwa Chemical Synthesis & Biotech Co's 5-Year Yield-on-Cost % too high?
Chunghwa Chemical Synthesis & Biotech Co's current 5-Year Yield-on-Cost % of 0.14 is 77% below median its 10-year median of 0.60. Over the past 10 years, this metric has ranged from a low of 0.12 to a high of 1.90. The Biotechnology industry median 5-Year Yield-on-Cost % is 1.60. Chunghwa Chemical Synthesis & Biotech Co's value of 0.14 is 91.3% below this industry median. Based on the distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #140 out of 150 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Chunghwa Chemical Synthesis & Biotech Co has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Chunghwa Chemical Synthesis & Biotech Co's 5-Year Yield-on-Cost % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Chunghwa Chemical Synthesis & Biotech Co ranks #140 out of 150 companies for 5-Year Yield-on-Cost %. This places Chunghwa Chemical Synthesis & Biotech Co in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 1.60. Chunghwa Chemical Synthesis & Biotech Co's value of 0.14 is 91.3% below this benchmark. Historically, Chunghwa Chemical Synthesis & Biotech Co's own 5-Year Yield-on-Cost % has ranged from 0.12 to 1.90 over the past decade. While the company's 10-year median is 0.60 vs. the industry median of 1.60, Chunghwa Chemical Synthesis & Biotech Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Biotechnology company?
The median 5-Year Yield-on-Cost % among Biotechnology companies is 1.60, based on 150 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chunghwa Chemical Synthesis & Biotech Co's current 5-Year Yield-on-Cost % of 0.14 is 91.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Chunghwa Chemical Synthesis & Biotech Co and its competitors. For the Biotechnology industry, the median 5-Year Yield-on-Cost % is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chunghwa Chemical Synthesis & Biotech Co's current 5-Year Yield-on-Cost % is 0.14, which is 77% below median its own 10-year median of 0.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chunghwa Chemical Synthesis & Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$30.68, compared to a current price of NT$36.10 — trading 17.7% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.14, which is 77% below median its 10-year median of 0.60 and 91.3% below the Biotechnology industry median of 1.60. Chunghwa Chemical Synthesis & Biotech Co's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Chunghwa Chemical Synthesis & Biotech Co (TPE:1762), the current 5-Year Yield-on-Cost % is 0.14 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chunghwa Chemical Synthesis & Biotech Co (TPE:1762) Overvalued in 2026?
Based on GuruFocus' analysis, Chunghwa Chemical Synthesis & Biotech Co stock appears to be overvalued.
The current stock price of NT$36.10 is trading 17.7% above its estimated GF Value™ of NT$30.68.
GuruFocus considers Chunghwa Chemical Synthesis & Biotech Co to be Modestly Overvalued.
Key valuation signals for TPE:1762:
5-Year Yield-on-Cost %: 0.14 (77% below median its 10-year median of 0.60)
GF Value™: NT$30.68 vs. price of NT$36.10 (17.7% above fair value)
Industry Position: 91.3% below the Biotechnology median (#140 of 150)
No single metric tells the full story. See the TPE:1762 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chunghwa Chemical Synthesis & Biotech Co Ltd is engaged in the research, development, manufacturing, and sales of pharmaceutical products. Geographically, it derives a majority of its revenue from the United States and also has a presence in Taiwan. Its product portfolio comprises pain management, antifungal, immunosuppressant, oncology, Cardiovascular, Peptide Drugs, and Others.
58GF Score
Get the complete analysis for TPE:1762
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1762 has been successfully added to your 
